차바이오텍 085660
망막 연구기관
ACT社 "망막특허취득"
"망막시장에 지배적 역할기대"
Advanced Cell Technology Awarded Broad Patent For Production of Retinal Pigment Epithelial Cells
June 16, 2010, WORCESTER, MA - Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs). Issued with 35 claims, the patent covers what the company believes are the fundamental methods for producing RPE cells from hESCs in a manner that is suitable for use in human patients. The Company expects to use RPE cells in its Phase I trial to treat patients with Stargardt’s Macular Dystrophy (SMD) and in other pre-clinical applications.
첫댓글 감사합니다.